New stem cell transplant approach shows promise for blood disorders

NCT ID NCT04523376

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a stem cell transplant from closely matched unrelated donors for 8 patients with severe sickle cell disease or thalassemia major. The donated stem cells were specially processed to remove certain immune cells to reduce the risk of rejection and graft-versus-host disease. The goal was to see if this approach could safely replace the patient's faulty blood cells with healthy donor cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stem cell transplant from a closely matched unrelated donor, processed to remove certain immune cells
What this could lead to
If successful, this approach could offer a way to control or potentially cure sickle cell disease and thalassemia for patients without a matched sibling donor.
What could go wrong
This was a very small pilot study (8 people) with no control group. Risks include graft failure, graft-versus-host disease, and serious infections. Results may not apply to larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA MAJOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.